Yu Quanheng, the Secretary of the Board of Directors of Garden Biopharmaceutical, stated at the 2024 annual performance briefing that the majority of the company's products exported to the United States are not subject to the tariff increase effective April 2 in the U.S. The adjustment of U.S. tariff policies has limited impact on the company's export business, but the company does not rule out the possibility of price increases. The main drivers of the company's future profit growth are the production of new products and the release of existing capacity. In 2025, the company will actively promote the construction of convertible bond fundraising projects, with major fundraising projects including biotin and VB6 expected to be put into production in the second and third quarters of this year